

31 March 2025

Dear Mr Dummy Sonny

We're writing to let you know about some changes we're making from 1 July 2025. These changes affect how we cover cancer supportive medicine, chemotherapy and hormonal treatment when a generic alternative is available.

We understand how important your treatment is, and we want to support you in every way possible. By introducing a reference price for these medicines, we aim to help you get the most benefit from your Oncology Programme.

What's changing?

We're introducing a reference price for these medicines. A reference price is the maximum amount we will pay for a group of generic or similar medicine.

This means that your treatment will stay the same, but the specific medicine you'll use will be one of the best-priced options. This helps you get the most out of your Oncology Benefit.

What this means for you:

- **You'll have full cover** if your medicine costs less than or the same as the reference price. This means we'll cover it completely.
- **You'll have a co-payment** if your medicine costs more than the reference price. You'll have to pay the difference between the reference price and the provider's price.

Why these changes are important

We want to help you get the best possible care while making sure that your treatment stays affordable. Generic alternatives often cost less than brand-name medicine, but they work just as well.

What you must do next

1. **Review your medicine:** We've listed your current medicine below.
2. **Consult your health provider:** Talk to your healthcare professional to understand your options.

Your medicine that will be affected by the reference price

What you are currently claiming	Information to help you decide if you must make a change
Oplaxin concentrate for solution 1ml via	Ask your dispensing pharmacist whether they can change your medicine to a better-priced alternative.
Zothena	
Abic leucovorin	
Phenergan	
Tagalon	
Tronson solution for injection vial	
Aprepitant combipack eurolab (1x125mg ca	
Adco-contromet	
Onicit vial 5ml	
Eurotax concentrate for solution for inf	

Contact us

For more details about your cancer cover, www.engenmed.co.za.

Your treating healthcare professional can advise you about on alternative medicine for your treatment.

Our priority is to make sure that you continue to get the best care possible, and we are here to help you navigate through these changes.

Regards

A handwritten signature in black ink, appearing to read 'N. Nematswerani', written in a cursive style.

Dr. Noluthando Nematswerani
Chief Clinical Officer | Discovery Health
On behalf of Engen Medical Benefit Fund